Prices delayed by at least 15 minutes | Print
Valirx PLC (VAL)
ORD 0.1PThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Company profile
ValiRx PLC is a UK-based biopharmaceutical and life sciences company focused on advancing cutting-edge therapies in healthcare. The Company mainly engages in developing technologies and products in oncology therapeutics and diagnostics, with a focus on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It develops therapeutics across fields in oncology and has a portfolio of products in the pipeline, including GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in different stages of development.
Address
16 Upper Woburn Place
London
GBR
WC1H 0BS
Telephone
+44 2030084416
Forecast key dates
| Name | Key Date |
|---|---|
| ValiRx PLC Second Quarter Earnings Results for 2027 | 2027-09-15T00:00:00 |
| ValiRx PLC Annual General Meeting for 2026 | 2027-07-16T10:00:00 |
| ValiRx PLC Fourth Quarter Earnings Results for 2026 | 2027-06-22T00:00:00 |
| ValiRx PLC Annual Report for 2026 | 2027-06-22T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| ValiRx PLC Second Quarter Earnings Results for 2026 | 2026-09-15T00:00:00 |
| ValiRx PLC Annual General Meeting for 2025 | 2026-07-17T10:00:00 |
| ValiRx PLC Fourth Quarter Earnings Results for 2025 | 2026-06-22T00:00:00 |
| ValiRx PLC Annual Report for 2025 | 2026-06-22T00:00:00 |